R1 Therapeutics debuted in March with an oversubscribed $77.5M Series A and one asset: AP306, a first-in-class phosphate-transporter inhibitor licensed out of Shanghai. Its phase 2a beat sevelamer head-to-head, and a global Phase 2b began July 21.
Autonomous 'self-driving labs' are turning drug discovery into a closed-loop infrastructure play — from NVIDIA and Lilly's $1B bet to ARPA-E's national Accelerate program.
PLD Space's €180M Series C makes it the best-funded contender in Europe's sovereign launch rebuild, ahead of Isar, MaiaSpace and a collapsing Orbex.
Robots proven in contested, hazardous environments are moving into substation inspection and maintenance. Is defence-grade autonomy the right template for civilian grids, or an over-engineered import?
A South Dakota startup is betting the carbon-capture prize is the enzyme, not the plant, as it moves from lab to a 2026 field pilot.
A guide to the 2026 AI infrastructure stack, and why the training-to-inference flip rewrote where the money sits.
ARX Robotics' GEREON UGS fleet is deployed by the Bundeswehr in NATO's Grand Eagle II exercise on the eastern flank. The 27-person startup is out-learning the defence primes on Ukraine's real-world feedback loop, and the ground-robotics prime slot is suddenly up for grabs.
Versa Vascular named ex-Medtronic CEO Bill Shields and lifted its AdapTR tricuspid repair Series C to $42 million, funding a U.S. Early Feasibility Study.